Coronavirus Gravy Train Comes Through Town - 500 Million Pre-Filled Syringes On the Way In 2021 - Declaration of War: Coronavirus

Ed.'s note: Attempt slowing down this coming mandatory coronavirus. As we've stated in a previous post, the coronavirus is going to be an extremely lucrative business model. This $138 million contract comes under the Defense production Act (DPA) that is legislation passed September, 1950 the Trump administration is using to "fight coronavirus." Apparently, a declaration of war on coronavirus has been declared and this is likely a non-bid contract between insiders at the DoD. The downside is that the DPA has been used to ramp up production of ventilators and it has been shown that ventilators are actually killing people hospitalized for coronavirus. These syringes are being manufactured for when a coronavirus vaccine is rolled out.

News update for 15 May 2020: Mr. Trump --- Prove It Exists, Define What It Is, or Go Home
________

Source: cryptogon

DOD Awards $138 Million Contract, Enabling Prefilled Syringes for Future COVID-19 Vaccine

May 13th, 2020

Via: U.S. Department of Defense:

Statement attributed to Lt. Col. Mike Andrews, Department of Defense spokesman:

"Today the Department of Defense and the U.S. Department of Health and Human Services, announce a $138 million contract with ApiJect Systems America for "Project Jumpstart" and "RAPID USA," which together will dramatically expand U.S. production capability for domestically manufactured, medical-grade injection devices starting by October 2020.

Spearheaded by the DOD's Joint Acquisition Task Force (JATF), in coordination with the HHS Office of the Assistant Secretary for Preparedness and Response, the contract will support "Jumpstart" to create a U.S.-based, high-speed supply chain for prefilled syringes beginning later this year by using well-established Blow-Fill-Seal (BFS) aseptic plastics manufacturing technology, suitable for combatting COVID-19 when a safe and proven vaccine becomes available.

By immediately upgrading a sufficient number of existing domestic BFS facilities with installations of filling-line and technical improvements, "Jumpstart" will enable the manufacture of more than 100 million prefilled syringes for distribution across the United States by year-end 2020.

The contract also enables ApiJect Systems America to accelerate the launch of RAPID USA manufactured in new and permanent U.S.-based BFS facilities with the ultimate production goal of over 500 million prefilled syringes (doses) in 2021. This effort will be executed initially in Connecticut, South Carolina and Illinois, with potential expansion to other U.S.-based locations. RAPID will provide increased lifesaving capability against future national health emergencies that require population-scale vaccine administration on an urgent basis.

RAPID's permanent fill-finish production capability will help significantly decrease the United States' dependence on offshore supply chains and its reliance on older technologies with much longer production lead times. These supplies can be used if a successful SARS-COV-2 vaccine is oral or intranasal rather than injectable."
________